Phage Safety Cohort Study

Phage Safety Cohort Study

This cohort study aims to describe the adverse events related to the use of bacteriophages to treat serious infections, data from the literature being almost non-existent on this subject.

All potential serious adverse events in compassionate cases will be collected, and classified as potentially related to surgery, to antibiotics, or to phages, with the help of the HCL pharmacovigilance center. In addition, biobanking of pre- and post-treatment blood specimens (bloods, serums and cells) will determine whether phage immunization is implicated in particular adverse events.

Inclusion Criteria:

• Patient 18 years of age or older with a serious infection treated at CRIOAc Lyon by phage therapy
• Patient who did not object to participating in the study
• Patients ayant un poids minimum de 46kg

Exclusion Criteria:

• Patients under guardianship/curatorship
• Patients deprived of liberty
• Pregnant or breastfeeding women